Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Inventory (2022 - 2024)

Atara Biotherapeutics filings provide 3 years of Inventory readings, the most recent being $10.7 million for Q4 2024.

  • On a quarterly basis, Inventory rose 9.78% to $10.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $10.7 million, a 9.78% increase, with the full-year FY2024 number at $10.7 million, up 9.78% from a year prior.
  • Inventory hit $10.7 million in Q4 2024 for Atara Biotherapeutics, down from $14.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $18.7 million in Q2 2024 to a low of $1.6 million in Q4 2022.
  • Median Inventory over the past 3 years was $9.7 million (2023), compared with a mean of $10.1 million.
  • Biggest five-year swings in Inventory: surged 511.98% in 2023 and later increased 9.78% in 2024.
  • Atara Biotherapeutics' Inventory stood at $1.6 million in 2022, then surged by 511.98% to $9.7 million in 2023, then rose by 9.78% to $10.7 million in 2024.
  • The last three reported values for Inventory were $10.7 million (Q4 2024), $14.0 million (Q3 2024), and $18.7 million (Q2 2024) per Business Quant data.